Priority Research Paper Volume 12, Issue 1 pp 8—34

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity

class="figure-viewer-img"

Figure 1. PD-L1 is abnormally glycosylated in response to resveratrol. (A) Representative immunoblot of PD-L1 protein in JIMT-1 cells cultured with or without metformin (1a), phenformin (1b), RSV (2), soraphen A (3), C75 (4), PP242 (5), Torin (6), AICAR (7), or compound C (8). (B, D) Representative immunoblots of PD-L1 protein in JIMT-1 cells cultured in the absence of presence of RSV, tunicamycin (TM), and/or cycloheximide (CHX), chloroquine (CLQ), and/or MG-132. (C) PD-L1 glycosylation patterns obtained from cell lysates of RSV-treated or untreated control cells that were further treated with PNGase F and Endo H and analyzed by western blotting (C: untreated control; black arrowhead, glycosylated PD-L1; *orange arrowhead, abnormal glycosylated PD-L1 form; **orange arrowhead, non-glycosylated PD-L1).